(19) INDIA

(22) Date of filing of Application :27/03/2024 (43) Publication Date : 05/04/2024

(54) Title of the invention: AN INTERLEUKIN-6 INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS

(51) International classification :A61P0037060000, A61P0029000000, A61P0019020000,

A61P0037020000

(86) International
Application No
Filing Date
(87) International

:NA
:NA

Publication No
(61) Patent of Addition
:NA

to Application Number :NA
Filing Date
(62) Divisional to

Application Number Filing Date :NA (71)Name of Applicant:

1)JSS COLLEGE OF PHARMACY, OOTY -JSS ACADEMY OF HIGHER EDUCATION & RESEARCH

Address of Applicant :POST BOX. No: 20 ROCKLANDS, OOTACAMUND, THE NILGRIS, TAMILNADU Ooty ------

Name of Applicant: NA Address of Applicant: NA (72)Name of Inventor: 1)JUBIE SELVARAJ

Address of Applicant: JSS COLLEGE OF PHARMACY, OOTY-JSS ACADEMY OF HIGHER EDUCATION & RESEARCH, Post Box No.: 20 Rocklands, Ootacamund, The Nilgris,

Tamilnadu-643001. Ooty -----

2)AKEY KRISHNA SWAROOP

Address of Applicant :JSS COLLEGE OF PHARMACY, OOTY-JSS ACADEMY OF HIGHER EDUCATION & RESEARCH, Post Box No.:20 Rocklands, Ootacamund, The Nilgris,

Tamilnadu-643001. Ooty ------

3)ESAKKIMUTHUKUMAR. M

Address of Applicant: JSS COLLEGE OF PHARMACY, OOTY-JSS ACADEMY OF HIGHER EDUCATION & RESEARCH, Post Box No.: 20 Rocklands, Ootacamund, The Nilgris,

Tamilnadu-643001. Ooty -----

4)NATARAJAN JAWAHAR

Address of Applicant :JSS COLLEGE OF PHARMACY, OOTY-JSS ACADEMY OF HIGHER EDUCATION & RESEARCH, Post Box No.:20 Rocklands, Ootacamund, The Nilgris,

Tamilnadu-643001. Ooty -----

(57) Abstract:

AN INTERLEUKIN-6 INHIBITOR FOR TREATING AUTOIMMUNE DISORDER An interleukin-6 inhibitor for treating autoimmune disorder pertains to an interleukin-6, a small-molecule IL-6 inhibitor for treating autoimmune disorders, more particularly, novel compounds which effectively inhibits Interleukin-6 also reduce the IL-6 levels in body mitigating inflammatory conditions. Interleukin-IL6 Inhibitor acts as a medium in the reduction and/or treatment of autoimmune conditions and demonstrates promising results in preclinical studies, offering a novel approach to addressing inflammatory and autoimmune disorders.

No. of Pages: 34 No. of Claims: 8